Related references
Note: Only part of the references are listed.Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation
Clifford Guy et al.
NATURE IMMUNOLOGY (2022)
The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm
Quentin Lecocq et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization
Mengzhou Guo et al.
FRONTIERS IN IMMUNOLOGY (2021)
Understanding LAG-3 Signaling
Luisa Chocarro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
Rodabe Navroze Amaria et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Elena Garralda et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
Ronglai Shen et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
LAG-3 Expression Predicts Outcome in Stage II Colon Cancer
Gaelle Rhyner Agocs et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
Andrea Botticelli et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity
Christopher E. Rudd et al.
CELL REPORTS (2020)
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
Matthew Kraman et al.
CLINICAL CANCER RESEARCH (2020)
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
Jason J. Luke et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
Niklas Kluemper et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Lawrence P. Andrews et al.
SCIENCE IMMUNOLOGY (2020)
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
Anne Froehlich et al.
EBIOMEDICINE (2020)
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jie Wang et al.
BLOOD (2020)
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
Victoria Atkinson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Colm Keane et al.
BLOOD ADVANCES (2020)
Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation
Takeo K. Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Lymphocyte Activation Gene-3 Maintains Mitochondrial and Metabolic Quiescence in Naive CD4+ T Cells
Dana M. Previte et al.
CELL REPORTS (2019)
Application of PD-1 Blockade in Cancer Immunotherapy
Xiaomo Wu et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56
Fan Zou et al.
NATURE COMMUNICATIONS (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood
Na Li et al.
CANCER BIOMARKERS (2018)
sLAG-3 in non-small-cell lung cancer patients' serum
Yayi He et al.
ONCOTARGETS AND THERAPY (2018)
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Takumi Maruhashi et al.
NATURE IMMUNOLOGY (2018)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
Jason B. Williams et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes
Qianxia Zhang et al.
SCIENCE IMMUNOLOGY (2017)
Reversing T-cell Dysfunction and Exhaustion in Cancer
Hassane M. Zarour
CLINICAL CANCER RESEARCH (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Ruea-Yea Huang et al.
ONCOTARGET (2015)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma
Weiqing Jing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
Feng Xu et al.
CANCER RESEARCH (2014)
Trafficking of LAG-3 to the Surface on Activated T Cells via Its Cytoplasmic Domain and Protein Kinase C Signaling
Joonbeom Bae et al.
JOURNAL OF IMMUNOLOGY (2014)
Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
Chiara Camisaschi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
CTLA-4 and autoimmunity: New insights into the dual regulator of tolerance
Jorge Romo-Tena et al.
AUTOIMMUNITY REVIEWS (2013)
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Nicola Gagliani et al.
NATURE MEDICINE (2013)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
Patrice Hemon et al.
JOURNAL OF IMMUNOLOGY (2011)
Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4
Seng-Ryong Woo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated lmmunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free Survival
Jana Kotaskova et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2010)
LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
Creg J. Workman et al.
JOURNAL OF IMMUNOLOGY (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
Metalloproteases regulate T-cell proliferation and effector function via LAG-3
Nianyu Li et al.
EMBO JOURNAL (2007)
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors
F Triebel et al.
CANCER LETTERS (2006)
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
M Kisielow et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Negative regulation of T cell homeostasisby lymphocyte activation gene-3 (CD223)
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2005)
Characterization of a novel C-type lectin-like gene, LSECtin - Demonstration of carbohydrate node
WL Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)
NY Li et al.
JOURNAL OF IMMUNOLOGY (2004)
Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2004)
The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells
CJ Workman et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination
F Triebel
TRENDS IN IMMUNOLOGY (2003)
Cutting edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2002)
Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)
S Andreae et al.
JOURNAL OF IMMUNOLOGY (2002)
Share Paper
